CVR 34462828Public limited company (A/S)Engroshandel med læge- og hospitalsartikler (464620)København NFounded 14 Mar 2012
Dandex has recorded no changes to this company since it began following the register.
Compiled by Dandex from the Central Business Register (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish company data. Connect it once and ask about ABBVIE A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set Up DandexEmployees
60
CVR registry, Aug 2026
+1 (+1.7%) over 12 months
Revenue
473M
DKK, annual report 2025
+40.4% on 2024
Result
+25M
DKK, annual report 2025
Equity
98M
DKK, annual report 2025
AbbVie Central Finance B.V.100% of capital and votes, since 31 May 2021
Thea Larsensince 14 Mar 2019
100% of capital and votessince 31 May 2021
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
100% of capital and votes1 Nov 2012 to 31 May 2021
ABBVIE A/S holds no Danish company now.
Found by searching the CVR owner register (ejerregister) for ABBVIE A/S as owner: Danish companies it holds 5% or more of, and their holdings one level down. Foreign holdings are not in CVR.
CVR 66675319100% of capital and votes6 Dec 2021 to 1 Apr 2022
CVR records founders at incorporation. It does not record whether they are alive or still involved.
29 Jan 2019 to 8 Nov 2026.
14 Mar 2012 to 8 Nov 2026.
Aug 2026, monthly: 60 employees, 56 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | 2012 | 2013 | 2014 | Jan 2015 | Feb 2015 | Mar 2015 | Apr 2015 | May 2015 | Jun 2015 | Jul 2015 | Aug 2015 | Sep 2015 | Oct 2015 | Nov 2015 | Dec 2015 | Jan 2016 | Feb 2016 | Mar 2016 | Apr 2016 | May 2016 | Jun 2016 | Jul 2016 | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Sep 2017 | Oct 2017 | Nov 2017 | Dec 2017 | Jan 2018 | Feb 2018 | Mar 2018 | Apr 2018 | May 2018 | Jun 2018 | Jul 2018 | Aug 2018 | Sep 2018 | Oct 2018 | Nov 2018 | Dec 2018 | Jan 2019 | Feb 2019 | Mar 2019 | Apr 2019 | May 2019 | Jun 2019 | Jul 2019 | Aug 2019 | Sep 2019 | Oct 2019 | Nov 2019 | Dec 2019 | Jan 2020 | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 | Oct 2021 | Nov 2021 | Dec 2021 | Jan 2022 | Feb 2022 | Mar 2022 | Apr 2022 | May 2022 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 78 | 94 | 100 | 100 | 102 | 110 | 100 | 101 | 99 | 100 | 100 | 102 | 99 | 99 | 97 | 97 | 100 | 108 | 88 | 92 | 92 | 91 | 89 | 89 | 92 | 91 | 90 | 89 | 88 | 112 | 86 | 89 | 87 | 87 | 87 | 88 | 86 | 84 | 86 | 83 | 84 | 103 | 89 | 86 | 84 | 82 | 82 | 82 | 85 | 89 | 89 | 85 | 85 | 93 | 82 | 78 | 78 | 69 | 61 | 62 | 51 | 48 | 56 | 53 | 48 | 65 | 50 | 49 | 54 | 50 | 48 | 52 | 47 | 50 | 54 | 48 | 48 | 57 | 52 | 46 | 49 | 46 | 46 | 50 | 45 | 48 | 46 | 48 | 53 | 55 | 59 | 60 | 60 | 61 | 61 | 60 | 59 | 59 | 58 | 58 | 58 | 62 | 57 | 58 | 54 | 54 | 56 | 56 | 53 | 53 | 53 | 52 | 52 | 61 | 51 | 51 | 52 | 49 | 53 | 50 | 49 | 49 | 66 | 52 | 55 | 61 | 56 | 56 | 56 | 56 | 59 | 60 | 58 | 59 | 59 | 59 | 59 | 66 | 62 | 61 | 60 | 59 | 60 |
| FTE | 19 | 81 | 93 | 94 | 94 | 102 | 94 | 95 | 93 | 95 | 93 | 94 | 91 | 92 | 92 | 90 | 91 | 98 | 79 | 82 | 83 | 82 | 80 | 82 | 81 | 83 | 83 | 81 | 81 | 92 | 77 | 80 | 79 | 79 | 78 | 79 | 77 | 77 | 75 | 74 | 74 | 86 | 78 | 76 | 76 | 73 | 71 | 75 | 76 | 77 | 78 | 73 | 75 | 80 | 71 | 68 | 70 | 62 | 54 | 53 | 40 | 41 | 47 | 45 | 43 | 53 | 45 | 45 | 44 | 42 | 40 | 38 | 40 | 42 | 42 | 41 | 41 | 46 | 44 | 41 | 40 | 40 | 40 | 40 | 40 | 41 | 41 | 43 | 47 | 49 | 54 | 55 | 54 | 56 | 50 | 55 | 54 | 52 | 52 | 53 | 53 | 57 | 54 | 54 | 51 | 51 | 51 | 52 | 49 | 50 | 50 | 48 | 49 | 57 | 49 | 49 | 48 | 47 | 47 | 48 | 47 | 46 | 50 | 49 | 52 | 60 | 54 | 54 | 55 | 55 | 55 | 57 | 57 | 57 | 59 | 59 | 59 | 64 | 61 | 61 | 60 | 57 | 56 |
| Series | Annual | Annual | Annual | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's own headcount as CVR records it, not the annual report's average, which may cover a group. Annual 2012 to 2014; monthly Jan 2015 to Aug 2026.
CVR changed its monthly method in Oct 2019, so a step at that month need not be real.
Latest Aug 2026, published 21 Oct 2026. Source: CVR employment series (Årsbeskæftigelse, Kvartalsbeskæftigelse, Månedsbeskæftigelse).
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 292,407 | 285,037 | 288,128 | 336,907 | 472,958 |
| Gross profit | Not reported | 81,696 | 77,195 | 75,124 | 106,210 |
| Operating profit | +14,298 | +15,040 | +16,546 | +16,846 | +34,118 |
| Result for the year | +11,194 | +12,206 | +13,735 | +11,056 | +25,024 |
| Equity | 183,992 | 196,198 | 61,932 | 72,988 | 98,012 |
| Total assets | 237,433 | 223,516 | 151,288 | 206,043 | 169,239 |
| Employees (average) | 48 | 52 | 52 | 48 | 55 |
| Credit metrics (Dandex calculations) | |||||
| Revenue growth (omsætningsvækst) | 59% | -2.5% | 1.1% | 16.9% | 40.4% |
| EBIT margin (overskudsgrad) | 4.9% | 5.3% | 5.7% | 5% | 7.2% |
| EBITDA | 14,531 | 15,400 | 16,877 | 17,221 | 34,409 |
| EBITDA margin | 5% | 5.4% | 5.9% | 5.1% | 7.3% |
| Employee growth (vækst i antal ansatte) | 14.3% | 8.3% | 0% | -7.7% | 14.6% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld) | -26,597note 1 | 0note 1 | Not reportednote 2 | 0note 1 | 0note 1 |
| Gearing, NIBD / EBITDA | Net cashnote 1 | Net cashnote 1 | Not reportednote 2 | Net cashnote 1 | Net cashnote 1 |
| ROIC (afkast af investeret kapital) | 7%note 1 | 6.6%note 1 | Not reportednote 2 | 17.5%note 1 | 30.2%note 1 |
| Capex (investeringer i anlægsaktiver) | 598note 3 | 2note 3 | 511note 4 | 711note 4 | Not reportednote 5 |
| Capex % of sales (investeringer i procent af omsætningen) | 0.2%note 3 | 0%note 3 | 0.2%note 4 | 0.2%note 4 | Not reportednote 5 |
| NIBD incl. group and owner balances (NIBD inkl. koncern- og ejermellemværender) | -150,336note 1 | -166,296note 1 | Not reportednote 2 | 91,064note 1 | 12,583note 1 |
DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages and gearing a multiple. Definitions. No cash flow statement: included in the group's (ÅRL § 86, stk. 4).
Annual report 2025
1 Jan 2025 to 31 Dec 2025, published 29 Jun 2026
Annual report 2024
1 Jan 2024 to 31 Dec 2024, published 26 Jun 2025
Annual report 2023
1 Jan 2023 to 31 Dec 2023, published 21 Jun 2024
Annual report 2022
1 Jan 2022 to 31 Dec 2022, published 26 Jun 2023
Annual report 2021
1 Jan 2021 to 31 Dec 2021, published 10 Jun 2022
Each registered value from the day it took effect, newest first.
Merger (Fusion), as the continuing company (Fortsættende selskab)
Demerger (Spaltning), as the receiving company (Modtagende selskab)
From CVR, read 8 Nov 2026. Text such as the signing rule and purpose is shown as registered.
20 registrations, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.
Ny adresse: Titangade 11, 2200 København N
Bestyrelse:
Fratrådte:
Emilie Claudine Demare, den 01.02.2024.
Tiltrådte:
Shitra Irari Amozurrutia Blancas, den 01.02.2024.
Bestyrelse:
Fratrådte:
Linn Kristina Mandahl, (formand), den 15.08.2023.
Tiltrådte:
Matthew Robert Iles, (formand), den 15.08.2023.
Vedtægter ændret: 26.06.2023
Vedtægterne er yderligere ændret
Vedtægter ændret: 01.04.2022
Nyt binavn: Allergan Aesthetics A/S
Bestyrelse:
Fratrådte:
Thea Larsen, den 01.04.2022, Linn Kristina Mandahl, den 01.04.2022, Robert Andrew Michael, (formand), den 01.04.2022.
Tiltrådte:
Arnaud Jean Jacques Coint-Bavarot, den 01.04.2022, Emilie Claudine Demare, den 01.04.2022, Jens Lange, den 01.04.2022, Linn Kristina Mandahl, (formand), den 01.04.2022.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående fusion.
Virksomheden er fusioneret med CVR-nummer: 66675319 ALLERGAN ApS, der samtidigt er opløst.
Vedtægter ændret: 01.04.2022
Selskabet tegnes af en direktør, et medlem af bestyrelsen eller af den samlede bestyrelse.
Erhvervsstyrelsen har modtaget erklæring fra vurderingsmændene om kreditorernes stilling angående den påtænkte fusion mellem CVR-nummer: 34462828 ABBVIE A/S (fortsættende) og CVR-nummer: 66675319 ALLERGAN ApS (ophørende). Modtagelse af fusionsplan er bekendtgjort den 22.12.2021.
I erklæringen antages det, at kreditorerne i CVR-nummer: 34462828 ABBVIE A/S og CVR-nummer: 66675319 ALLERGAN ApS må antages at være tilstrækkeligt sikrede efter fusionen.
Direktion:
Fratrådte:
Christina Dyreborg Jeppesen, den 14.03.2019.
Tiltrådte:
Thea Larsen, den 14.03.2019.
Bestyrelse:
Fratrådte:
Christina Dyreborg Jeppesen, den 29.01.2019, Tom Schjødt, den 29.01.2019, William Joseph Chase, (formand), den 29.01.2019.
Tiltrådte:
Thea Larsen, den 29.01.2019, Linn Kristina Mandahl, den 29.01.2019, Robert Andrew Michael, (formand), den 29.01.2019.
CVR-nummer:
34462828.
NAVN:
ABBVIE A/S.
Adresse: Emdrupvej 28C, 2100 København Ø.
Kommune: København.
Vedtægter ændret: 29.05.2015
Bestyrelse:
Udtrådt af bestyrelsen:
Thomas Craig Freyman, den 01.01.2013.
Indtrådt i bestyrelsen:
William Joseph Chase (formand), den 01.01.2013.
Vedtægter ændret:
01.10.2012.
Kapitalforhøjelse:
kr. 1.000,00 indbetalt ved spaltning, kurs 3.572.800,00.
Kapitalen udgør herefter kr. 501.000,00.
Aktiver og gæld er overdraget fra CVR-NR. 31528615 ABBOTT LABORATORIES A/S.
Erhvervsstyrelsen har modtaget spaltningsplan
for den påtænkte spaltning af
CVR-NR. 31528615 ABBOTT LABORATORIES A/S, der tillige driver virksomhed under navnene MEDISENSE A/S, ABBOTT PRODUCTS A/S.
De øvrige deltagende selskaber er:
CVR-NR. 34462828 ABBVIE A/S (modtagende).
Erhvervsstyrelsen har modtaget erklæring fra
Vedtægter ændret:
10.04.2012.
Nyt navn:
ABBVIE A/S.
Vedrørende det under 21.03.2012 registrerede selskab CVR-nr. 34462828 WCA PHARMACEUTICALS A/S meddeles, at formålet blev registreret forkert. Selskabet formål er: Selskabets formål er at drive handel med farmaceutiskeprodukter, hospitalsprodukter og diagnostik samt udvikle, producere og markedsføre teknologi og know-how. Selskabet kan derudover yde tjenesteydelser og assistance, herunder af administrativ, driftmæssig, finansiel, forretningsmæssig, videnskabelig eller industriel karakter, i tilknytning til selskabets formål til tredjemænd, aktionærer, datterselskaber eller tilknyttede selkaber.
CVR-NR. 34462828.
NAVN: WCA PHARMACEUTICALS A/S.
ADRESSE: Emdrupvej 28C, 2100 København Ø.
Kommune:
København.
Stiftelsesdato:
14.03.2012.
Seneste vedtægtsdato:
14.03.2012.
Kapital:
kr. 500.000,00.
Indbetalingsmåde:
Indbetalt kontant kr. 500.000,00 til kurs 100,00.
Stifter:
WCA PHARMACEUTICALS INVESTMENTS S.à.r.l, den 14.03.2012.
Bestyrelse:
Thomas Craig Freyman (formand), den 14.03.2012, Christina Dyreborg, den 14.03.2012, Civiløkonom Tom Schjødt, den 14.03.2012.
Direktion:
Christina Dyreborg, den 14.03.2012.
Selskabet tegnes af en direktør og et medlem af bestyrelsen i fællesskab eller af den samlede bestyrelse.
Revision:
CVR-NR. 33963556 DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB, Weidekampsgade 6, 2300 København S, den 14.03.2012.
Første regnskabsår:
14.03.2012 - 31.12.2012.
Regnskabsår:
01.01 - 31.12.
1 registered in CVR.
P-number 1017558052Titangade 11, 2200 København N
No other current company drawn.
No other current company drawn.
No other current company drawn.